About CRI

Paul J. Sekhri

Head, Biotech Ops Group
TPG Biotechnology
TPG Growth, LLC
San Francisco, CA

Prior to joining TPG Biotech in 2009, Mr. Sekhri was president and chief executive officer of Cerimon Pharmaceuticals. Prior to founding Cerimon, Mr. Sekhri was president and chief business officer of ARIAD Pharmaceuticals, Inc. In 2002, Mr. Sekhri joined the Sprout Group, the venture affiliate of Credit Suisse First Boston in New York, where he was a partner for healthcare technology investments. Prior to joining Sprout, Mr. Sekhri spent four years at Novartis, most recently as senior vice president and head of Global Search and Evaluation, Business Development and Licensing for Novartis Pharma AG. Prior to this, Mr. Sekhri set up a new department, Early Commercial Development, in order to ensure the differential competitive advantage of Novartis’ pipeline. Mr. Sekhri completed graduate work in neuroscience at the University of Maryland, School of Medicine where he also received his B.S. in Zoology.

Mr. Sekhri is currently a member of the Board of Directors for ARYx Therapeutics, A.P.T. Pharmaceuticals, and KAI Pharmaceuticals. Additionally, he is on the Board of Directors of the Cancer Research Institute, a member of the Advisory Board for The BioExec Institute, Inc and an advisor to the Brookings Global Health Financing Initiative.

Mr. Sekhri was a board member of the Irvington Institute for Immunological Research, and joined Cancer Research Institute board in October 2007 when the two organizations merged.